Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,218.00
(
1.73%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
98.41
(
1.75%
)
Bitcoin
78,125.99
(
-0.15%
)
News Focus
News Focus
Post# of 236585
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

JLA Ins

Send PM Follow Ignore
Followers 18
Posts 939
Boards Moderated 0
Alias Born 05/09/2020

JLA Ins

Re: moneycrew post# 129424

Saturday, 11/14/2020 5:35:46 PM

Saturday, November 14, 2020 5:35:46 PM

Post# of 236585
Email I received back from 10/29

Thank you for your follow-up email to the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health.

Please note that discussions are ongoing about leronlimab and its potential for COVID-19.

Sincerely,


Kara M. Harris, MPH
Section Chief for Controlled Correspondence and Public Inquiries
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CYDY News
More CYDY News